Generate Biomedicines, Inc. balance sheet GENB

As of Jun 30, 2026, Generate Biomedicines, Inc. had total assets of $561.7 million and total liabilities of $105.6 million. Stockholders' equity was $456.0 million. It held $457.4 million in cash and investments against $62.6 million of total debt, net cash of $394.8 million. The current ratio, current assets divided by current liabilities, was 8.30.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
Assets
Cash
135
Short-term investments
322
Cash and investments
457
Total current assets
470
Property and equipment, net
27
Total assets
562
Liabilities and equity
Accounts payable
6
Total current liabilities
57
Total liabilities
106
Stockholders' equity
456
Debt
Lease liabilities
63
Total debt
63
Net cash
395
Ratios
Current ratio
8.30x
Debt to equity
0.14x
Book value per share
3.56
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
GENB (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Somerville, MA
SEC filer status
, Emerging growth company
SEC CIK
2100782

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.